Globally, the public health burden of congenital syphilis (CS) remains high despite efforts to eliminate mother-to-child transmission (EMTCT) of syphilis and the fact that this disease is treatable if diagnosed early. In the WHO European region, the burden is not fully available, as CS cases are not systematically reported by the non-EU/EEA countries, while data from the European Union and European Economic Area (EU/EEA) countries are regularly reported by the European Centre for Disease Prevention and Control. In 2023, only 8 out of 24 non-EU/EEA countries reported the number of CS cases to Global AIDS Monitoring. In 2024, the WHO Regional Office for Europe conducted a survey among the 24 non-EU/EEA countries. Based on the data from 19 countries, the total number of CS cases was 93 (2.8 per 100,000 live births) in 2023. Seven countries reported no cases between 2021 and 2023, and four countries accounted for 84% of the cases. The actual burden of CS could be higher because of the suboptimal surveillance systems and variation in case definition used for surveillance. The survey results underline the importance of strengthening CS surveillance in non-EU/EEA countries, including standardising the case definition and improving completeness and coverage.

The authors have declared no competing interest.

Not applicable

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes